Advancing Precision Dosing of 5-FU: Population PK Model Development, Limited Sampling Strategies, and Fit-for-Use Application [0.03%]
5-氟尿嘧啶精准给药人群PK模型构建、样本集选择及应用研究
Zhiyuan Tan,Aymara Sancho-Araiz,Swantje Völler et al.
Zhiyuan Tan et al.
Background: A significant proportion of patients receiving 5-fluorouracil-based chemotherapy have been reported to experience grade ≥ 3 toxicities, which range from 21 to 76% depending on the treatment regimen. This may ...
Correction: Model‑Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness [0.03%]
纠正：基于模型的替代给药策略以提高皮下注射尼伏单抗的成本效益
Yan Wang,Laura H Bukkems,Rob Ter Heine et al.
Yan Wang et al.
Published Erratum
Clinical pharmacokinetics. 2026 May 19. DOI:10.1007/s40262-026-01649-x 2026
Therapeutic Drug Monitoring of Imatinib in Paediatric Chronic Myeloid Leukaemia: Towards Practical Implementation and Interpretation of Measured Plasma Concentrations [0.03%]
伊马替尼在儿童慢性髓系白血病治疗性药物监测中的实际应用及血液浓度测定结果解读路径
Phyllis Lensker,Andrea Gottschalk,Thomas Zerjatke et al.
Phyllis Lensker et al.
Background and introduction: Imatinib (IMA) revolutionised the treatment of chronic myeloid leukaemia (CML). Therapeutic drug monitoring (TDM) of IMA is recommended to improve treatment outcomes in adults, but guidance fo...
Development and Clinical Application of a Real-World Population Pharmacokinetic Model of Rivaroxaban in Asian Patients with Atrial Fibrillation [0.03%]
亚太心房颤动患者达比加群药物暴露的真实世界人群药代动力学模型的开发及其临床应用
Nian-Shiuan Lai,Chun-Jung Lin,Ching-Hua Kuo et al.
Nian-Shiuan Lai et al.
Background: Rivaroxaban, a factor Xa inhibitor, is used to prevent stroke in patients of atrial fibrillation (AF). This study aimed to establish a population pharmacokinetic (PPK) model for rivaroxaban using real-world da...
Population Pharmacokinetic/Pharmacodynamic Modeling of Therapeutic Enzymes in Lysosomal Storage Diseases [0.03%]
溶酶体贮积病治疗酶的群体药动/药效学模型研究
Ina Barzel,Ans T van der Ploeg,W W M Pim Pijnappel et al.
Ina Barzel et al.
Background: Lysosomal storage diseases (LSDs) are rare genetic disorders treated with enzyme replacement therapy (ERT). However, treatment outcomes are highly variable, reflecting the complexities of therapeutic enzyme ph...
Precision Dosing of Vancomycin: A Systematic Review of Population Pharmacokinetics Models and Comparative Evaluation of Software Tools [0.03%]
万古霉素精准用药的系统评价及软件工具比较评估
Nada Dia,Yannick Hoffert,Angela Elma Edwina et al.
Nada Dia et al.
Background and objectives: Vancomycin is a widely used antibiotic with a narrow therapeutic window and considerable pharmacokinetic variability, necessitating accurate and precise dosing. Population pharmacokinetics (popP...
Effect of Enzalutamide on Morphine Exposure in Patients with Prostate Cancer [0.03%]
恩扎卢胺对前列腺癌患者吗啡暴露的影响
Catharina J P Op &#x;t Hoog,Niven Mehra,Benthe van der Weij et al.
Catharina J P Op &#x;t Hoog et al.
Background and objective: Pain management in patients with prostate cancer receiving enzalutamide is challenging owing to its high potential for drug-drug interactions. Morphine is generally preferred because of its favor...
Evaluating Bayesian Vancomycin Dosage Adjustment in Neonates: A Simulation-Based Virtual TDM Study [0.03%]
基于模拟的虚拟TDM评估新生儿万古霉素贝叶斯剂量调整效果的研究
Anne Ravix,Yann Thoma,Annie Cathignol et al.
Anne Ravix et al.
Background and objectives: Therapeutic drug monitoring (TDM) of vancomycin, ideally based on the ratio of the daily area under the curve to the minimal inhibitory concentration at steady state (AUC24,SS/MIC), is hindered ...
Impacts of Uremic Toxins on the Population Pharmacokinetics of Total Mycophenolic Acid and its Glucuronide Metabolite in Adult Kidney Transplant Recipients [0.03%]
尿毒症毒素对成人肾移植受者霉酚酸及其葡萄糖醛酸代谢物群体药代动力学的影响
Ala&#x;a R Al-Dajani,Yan Rong,Jinal Adhiya et al.
Ala&#x;a R Al-Dajani et al.
Background and objective: Mycophenolic acid (MPA) exhibits considerable inter-individual variability in drug exposure, which can result in acute graft rejection as well as hematological or infectious adverse effects. Evid...
Population Pharmacokinetics of Sacubitril/Valsartan in Patients with Heart Failure and End-Stage Renal Disease Undergoing Peritoneal Dialysis [0.03%]
在进行腹膜透析的终末期肾病和心力衰竭患者中沙库必曲/缬沙坦的群体药代动力学特征
Ying Jin,Nuo Xu,Wenyu Yang et al.
Ying Jin et al.
Background and objective: Cardiovascular risk is markedly increased in end-stage renal disease. Although sacubitril/valsartan provides cardiovascular benefits in heart failure, evidence supporting its use in end-stage ren...